Back to News
Market Impact: 0.2
Adagene Begins Phase 1 Trial Of Muzastotug Plus INCA33890 In MSS Colorectal Cancer; Stock Up
Source: Nasdaq
Healthcare & Biotech
Adagene reported that the first patient has been dosed in a Phase 1 study of muzastotug combined with Incyte's INCA33890 in patients with microsatellite stable colorectal cancer. The announcement marks initiation of the clinical study; no efficacy or safety results were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ADAG0.50
INCY0.20
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Dassault Systèmes raises 2026 outlook as revenue growth rebound gathers pace
- Needham initiates Clover Health stock with buy on cohort economics